Kornimate/medical-research-clean huggingface dataset:
new findings about somatosensory evoked potentials (sep) during surgery for cerebral aneurysms

Conditions: Cerebral Aneurysm

Summary: during surgery, electrophysiological signals will be acquired with the instrument (isis iom, neuroexplore, software version 4.4, inomed) already in use at the neurosurgery service of the neurocentro of the hospital civic italian switzerland in lugano. simultaneously to somatosensorial evoked potential (sep) will also be recorded the electroencephalography (eeg) activity with the same detection of locations. for the purposes of the study the signals transmitted to the neurosurgeon through the hardware and the corresponding assessments done by the neurophysiologist responsible for intraoperative monitoring will be recorded. it will also be kept track of procedures performed during surgery.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * patient bearer of a not broken cerebral aneurysm, which has been defined per size and morphology susceptible to surgery * aneurysms located on cerebral arteries of the anterior circulation (carotid, middle cerebral arteries, anterior cerebral, anterior communicating, pericallose); cases of multiple aneurysms are also eligible * informed consent for participation in the study exclusion criteria: * patient with an aneurysm of the posterior circulation (vertebrobasilar system) * the aneurysm was a source of bleeding (subarachnoid hemorrhage, intracerebral, intraventricular). * patient with a pace-maker (for the risk that the electric currents used in the study could compromise the operation of the pace-maker)
qlb after nephrectomy

Conditions: Pain, Postoperative; Chronic Postoperative Pain

Summary: oxycodone consumption and postoperative pain intensity in patients undergoing nephrectomy procedures. of all study participants, 50% will obtain quadratus lumborum block (qlb).

patients undergoing nephrectomy procedures will be allocated to one of the study arms. at the end of an operation, still under general anesthesia, 50% patients will obtain qlb with ropivacaine. ultrasound-guided qlb will be performed on the side of surgery with 0.375% ropivacaine solution (0.2 ml per kg). every patient will get patient-controlled analgesia pump with oxycodone in the postoperative period. postoperative pain will be measured with vas (visual-analogue scale) 2, 4, 8, 12 and 24 hours after the end of the operation. 24 -hours period. at the 1, 3, 6 months patients will be interviewed by phone to assess neuropathic pain. neuropathic pain symptom inventory (npsi) will be used.

Eligibility criteria:
inclusion criteria: * obtained consent * nephrectomy procedure exclusion criteria: * coagulopathy allergy to local anesthetics depression, antidepressant drugs treatment epilepsy usage of painkiller before surgery addiction to alcohol or recreational drugs
a feasibility study on the safety and preliminary efficacy of bilateral subthalamotomy using mrgfus for treatment of pd

Conditions: Parkinson Disease; Neurologic Manifestations

Summary: the objective of this study is to test the safety and preliminary efficacy of staged bilateral subthalamotomy performed using the exablate transcranial system for the treatment of parkinson's disease (pd) motor features

the objective of this study is to evaluate the incidence and severity of adverse events (ae/aes) associated with exablate transcranial magnetic resonance guided focused ultrasound (mrgfus) bilateral staged subthalamotomy for the treatment of pd motor features. to determine the effectiveness of the exablate transcranial staged bilateral subthalamotomy to treat cardinal motor features of subjects with pd.

Eligibility criteria:
inclusion criteria: 1. male or female age 30 years or older 2. able and willing to give consent and able to attend all study visits 3. a confirmed diagnosis of parkinsons disease 4. subjects that have received unilateral subthalamotomy at least 6 month before the inclusion in bilateral subthalamotomy and present parkinsonian symptoms 5. able to localize subthalamic nucleus on mri for treatment 6. able to communicate sensations during the exablate mrgfus procedure exclusion criteria: 1. hoehn and yahr stage in the on medication state of 2.5 or greater 2. presence of severe dyskinesia as noted by mds-updrs scores 3. presence of other central neurodegenerative disease 4. parkinsonian symptoms are a side effect from neuroleptic medications 5. subjects exhibiting any behavior(s) consistent with ethanol or substance abuse 6. history of a bleeding disorder or receiving anticoagulant 7. subjects with advanced kidney disease or on dialysis 8. subjects with known intolerance or allergies to the mri contrast agents. 9. presence of unknown or mri unsafe devices anywhere in the body. 10. history of multiple strokes, or a stroke within past 6 months 11. subjects with a history of seizures within the past year 12. subjects with malignant brain tumors 13. women who are pregnant or nursing

Keywords: mrgfus exablate parkinsons disease sub-thalamotomy
the efficacy of tamsulosin and tadalafil compared to placebo in the treatment and prevention of urinary disorders after transperineal prostate biopsy

Conditions: Lower Urinary Tract Symptoms; Voiding Disorders; Pain; Quality of Life

Summary: the purpose of this study is to evaluate the therapeutic efficacy of tamsulosin and tadalafil compared to placebo in the treatment and prevention of urinary disorders after transperineal prostate biopsy

after being informed about the clinical study and all the risks, all patients will be given a written informed consent. they will be randomised in three groups: a (tadalafil),b (tamsulosin) and c (placebo) and the drug or placebo will be administrated seven days before and seven days after transperineal prostate biopsy. thirty minutes before the biopsy, all patients will receive a prophylactic antibiotic (ceftriaxone 2g intravenously) and an analgetic ( naklofen 75mg intramuscular injection). before the biopsy patients will do an uroflowmetry to determine the qmax and ultrasound(us) of the urinary tract to determine residual urine. after the biopsy is performed the patient fills out the international prostate symptom score (ipss/qol), visual analog scale (vas) for pain, international index of erectile function (iief-5) and 36-item short form survey (sf-36) questionnaires. seven days after the biopsy the patient discontinues with the therapy and makes a visit for routine control of uroflowmetry, us of the urinary tract and he previously mentioned questionnaires are filled out. after 30 days of the biopsy the patient makes a visit for regular control of the pathohistological findings, uroflowmetry and ultrasound of the urinary tract, along with filling out the questionnaires again.

Eligibility criteria:
inclusion criteria: * every patient that is a candidate for first time prostate biopsy exclusion criteria: * previous complaints of the lower urinary tract; benign prostatic hyperplasia(bph), overactive bladder (oab), etc. * previous urinary retention and catheterization * previous prostate biopsies * patients who were treated surgically or medically for bph * systemic diseases including uncontrolled diabetes * neurological diseases * hemorrhagic diathesis * patients on anticoagulants therapy * patients with urinary infections
menopause sample collection

Conditions: Menopause

Summary: this study will provide daily urine samples from women during early and late stage peri-menopause as well as post-menopause over the course of three calendar months in order to maintain the spd sample bank. urine samples will be received in the clinical laboratory and aliquoted into 2.25ml amounts and stored at -80˚c until required. symptom information will also be recorded to determine whether there are any noticeable physiological changes that can be related to stage of the menopause.


Eligibility criteria:
inclusion criteria: * female * between the ages of 45 and 60 years * suspects they are going through or have been through the menopause * experiencing cycle irregularities: * early stage peri-menopause: mild cycle irregularity over the last 3-6months (minimum), variation of \>6 days in length between consecutive cycles including shortened and longer cycles (but not \>60 days in length) * late stage peri-menopause: irregular cycles with prolonged periods of amenorrhea \>60 days in length (but less than 12 months) * post-menopause: greater than 12 months since last menstrual period * willing to give informed consent exclusion criteria: * use of hormone replacement therapy (hrt) * use of hormone contraception * hysterectomy and/or oophorectomy * pregnant or breast feeding * other medical reason for amenorrhea (absence of menstruation)
an extension study to examine the safety and tolerability of a new drug in patients with symptoms of overactive bladder (oab).

Conditions: Overactive Bladder

Summary: this study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in participants with oab for up to 52 weeks.


Eligibility criteria:
inclusion criteria: 1. has completed participation in study rvt-901-3003. 2. has demonstrated ≥ 80% compliance with self-administration of study treatment in study rvt-901-3003. exclusion criteria: 1. has a change in history or current evidence of any clinically significant condition, therapy, lab abnormality, or other circumstance that might, in the opinion of the investigator, confound the results of the study, interfere with the participant's ability to comply with study procedures, or make participation in the study not in the participant's best interest. 2. has coronary or neurovascular interventions planned during the duration of the study. 3. has uncontrolled hyperglycemia (defined as fasting blood glucose \>150 mg/dl or 8.33 mmol/l and/or non-fasting blood glucose \>200 mg/dl or 11.1 mmol/l) based on most recent available lab results in study rvt-901-3003 or, if in the opinion of the investigator, is uncontrolled. 4. has uncontrolled hypertension (systolic blood pressure of ≥ 180 mm hg and/or diastolic blood pressure of ≥ 100 mm hg) or has a resting heart rate (by pulse) \> 100 beats per minute. 5. has clinically significant ecg abnormality which, in the opinion of the investigator, exposes the participant to risk by participating in the study 6. has alanine aminotransferase or aspartate aminotransferase \> 2.0 times the upper limit of normal (uln), or bilirubin (total bilirubin) \> 1.5 x uln (or \> 2.0 x uln if secondary to gilbert syndrome or pattern consistent with gilbert syndrome) based on most recent available lab results in study rvt-901-3003. 7. has an estimated glomerular filtration rate (egfr) \< 30ml/min/1.73 m2 based on most recent available lab results in study rvt-901-3003. 8. use of any prohibited medications as detailed in section 7.7.3. 9. plans to initiate or change the dosing of any medications listed in section 7.7.5 during the study that in the opinion of the investigator is assessed to be clinical significant. 10. has an allergy, intolerance, or a history of a significant clinical or laboratory adverse experience associated with any of the active or inactive components of the vibegron formulation or tolterodine formulation. 11. is currently participating or has participated in a study with an investigational compound or device within 28 days of signing informed consent, not including participation in study rvt-901-3003. 12. has a history of significant drug or alcohol abuse/dependence within a year of informed consent, as assessed by the investigator. 13. has a varying sleep schedule anticipated during times when the voiding diaries are to be completed.

Keywords: beta-3 adrenergic receptor (β3-ar) agonists incontinence oab vibegron urge urinary incontinence urinary bladder, overactive urologic diseases lower urinary tract symptoms urological agents
mental health pathways in internet support groups

Conditions: Depression; Stress; Anxiety

Summary: people facing serious health threats increasingly use internet health support communities to obtain informational support, emotional support and other resources. this study introduces software algorithms similar to those used by social media sites to put people in touch with helpful information and social interactions. participants from the american cancer society's cancer support network will have access to this online support group using the default interface that orders content by broad content category and date or with a new interface that highlights communication content and people that match users' interests and needs.

internet support groups (isgs) are online communities where people come together to exchange information, emotional support and other resources. they are an important resource for patients grappling with serious medical conditions. although participation in health-related isgs has been associated with significant reductions in participant-reported depression, anxiety and other indicators of psychological distress, many isg members leave too soon to benefit. in a parallel study, we are using state-of-the art machine learning and automated language analysis techniques to assess the types of interactions that keep people participating in these groups and that lead to improved psychosocial well-being and health quality of life and how these interactions develop. the clinical trial described here uses these technologies and insights from our empirical research to build, deploy, and evaluate interventions that improve the interactions in internet health support groups. we will develop and pilot-test interventions to encourage effective communication processes identified in our empirical research. participants from the american cancer society's cancer support network will access this support group using either the default interface that orders content by disease diagnosis and date or with a new interface that sometimes highlights communication content and people who match their interests and needs. we will test whether mood, satisfaction with interactions and engagement in the group increase following interventions that (a) increase participants' receipt of individualized support from others; (b) provide participants with opportunities to offer support to others; (c) facilitate participants' expression of emotions; and (d) help participants form relationships with compatible peers. in a series of small, randomized experiments, we will examine how these interventions affect participants' communication behaviors as well as short-term engagement and satisfaction with their online interactions.

Eligibility criteria:
inclusion criteria: * is an existing or new registrant to the american cancer society's cancer support network. exclusion criteria: -

Keywords: social support
study of immune responses to influenza vaccination

Conditions: Influenza Vaccination

Summary: better understanding of the immune responses to influenza vaccination is needed in order to understand situations of poor vaccine response. adults will receive influenza vaccination and then have peripheral blood drawn at pre-defined intervals in order to study the lymphocyte responses.


Eligibility criteria:
inclusion criteria: * community-dwelling adults able to provide consent who need influenza vaccination for standard of care exclusion criteria: * febrile illness at time of vaccination * active malignancy * use of immunosuppressing medications * blood donation in the past 60 days * influenza vaccinated during the preceding 6 months * allergic reactions to influenza vaccination
the effect of education and reminder messages on the fatigue level of individuals with copd

Conditions: Copd; Fatigue

Summary: copd is an important respiratory system disease that progresses with damage to the airways.increased mucus secretion and thickening in the airways causes obstruction.this obstruction causes symptoms such as shortness of breath, cough, phlegm and wheezing.the most obvious problem that the emerging symptoms will cause for the patient is fatigue.coping with fatigue is an important problem in copd. the main questions it aims to answer are: 1. does the training given in copd affect the level of fatigue? 2. do the education given and text messages sent regarding copd affect the level of fatigue? in this study, patients were given informative education about copd and ways to cope with fatigue were explained. then, in order to increase the permanence of the training, motivational messages and short briefings were continued for 8 weeks.2 messages were sent per week. three groups were created to reveal the effectiveness of the trainings and messages. group 1 was trained and messages were sent for 8 weeks. group 2 was trained and no message was sent. group 3 is the control group. no training has been provided other than routine maintenance. the initial information of all groups was taken again at the end of the 8th week. main outcomes: * dyspnea severity, * copd general conditions and * fatigue level. the results obtained will be interpreted by comparing between 3 groups.


Eligibility criteria:
inclusion criteria: * diagnosed with copd for the last 1 year * hospitalized for at least 3 days, * voluntary patients exclusion criteria: * under 18 years old * over 85 years old * those with chronic fatigue syndrome * those with severe heart failure * those who had surgery in the last 6 months

Keywords: copd fatigue dyspnea training message
accuracy, feasibility and acceptance of continuous glucose monitoring in critically ill patients

Conditions: Glucose Metabolism Disorders; Diabetic Blood Glucose Monitoring; Critical Illness

Summary: critically ill patients are on high risk for increased serum glucose levels, leading to more comorbidity and higher mortality risk. in patients with severe sepsis and septic shock hyperglycemia is a typical finding. however the need of insulin therapy is associated with an increased risk of hypoglycemia. newly developed technologies for continuous glucose monitoring in critically ill patients may improve glycemic control and reduce glucose variability. the investigators will perform continuous glucose monitoring in critically ill patients on icu. measurements will be done for a period of 72h per patient. the investigators aim is to evaluate accuracy feasibility and acceptance of these methods. to analyze accuracy sensor glucose levels will be validated due to arterial blood gas measurements with the blood gas analyzer. the investigators will investigate the influence of several factors like oedema, perspiration, bmi, body temperature, ph-value application of vasoconstrictors on accuracy and feasibility of the particular system. furthermore nursing staff will be given a questionnaire to identify acceptance.


Eligibility criteria:
inclusion criteria: * critically ill patients with expected icu stay for more than 72 hours * informed consent by the patients or legal proxy exclusion criteria: * age \< 18 * no informed consent by the patients or legal proxy * pregnancy * infaust prognosis
assessing the feasibility of a whole health coaching intervention for veterans with chronic multisymptom illness

Conditions: Chronic Multisymptom Illness

Summary: this study examines the impact of a clinical whole health coaching program aimed at improving veteran's health and well-being by promoting engagement/adherence with clinical recommendations and increasing healthy lifestyle behaviors in treatment-seeking veterans receiving care at the dc and ca war related illness and injury study centers.


Eligibility criteria:
inclusion criteria: •veterans receiving a clinical evaluation at the war related illness and injury study centers in washington, dc or palo alto, california. exclusion criteria: * current active suicidal or homicidal ideation * current or lifetime history of a psychiatric disorder with primary psychotic features * current or lifetime bipolar disorder * acute or unstable psychiatric condition(s) and/or chronic illnesses that would benefit from immediate referral for treatment * neurological disorders such as alzheimer's disease, advanced parkinson's disease, and unstable epilepsy * pregnancy * current exposure to trauma, or exposure to trauma in the past 3 months * current or within the past 30 days substance abuse or dependence (except nicotine) * excessive alcohol intake defined as an audit score ≥ 4 for men and an audit score ≥ 3 for women.

Keywords: health coaching, chronic multisymptom illness
agility lp ankle arthroplasty outcomes

Conditions: Rheumatoid Arthritis of Ankle; Osteoarthritis of Ankle; Traumatic Arthritis of Ankle

Summary: this is a research study which is being done to determine the outcomes following agility lp ankle replacement. this implant was approved by the fda in 2007 and has been used since then with good early results. you are being asked to volunteer for this study because you have undergone total ankle arthroplasty with agility lp prosthesis. the purpose of the study is to compare the range of motion, level of pain and function during daily living prior to and after your ankle surgery.


Eligibility criteria:
inclusion criteria: * over 18 years old * can comprehend and sign the informed consent * patient must have undergone agility lp ankle replacement between january 2006 to june 2008 exclusion criteria: * patient has had following procedures on the study limb within two years of taa * revision of taa * ankle arthrodesis * amputation * agility lp arthroplasty was done as a revision procedure for a failed taa or as a takedown of ankle fusion. * any condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the study.

Keywords: ankle arthritis total ankle arthroplasty agility lp,